Drug details
Ozempic (semaglutide injection)
type of Antidiabetics, Glucagon-like Peptide-1 Agonists
Ozempic (semaglutide) Injection is a glucagon-like peptide 1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
This drug may have the following side effects:
- difficulty breathing,
- nausea,
- rash,
- vomiting,
- lightheadedness,
- shortness of breath,
- confusion,
- chills,
- dizziness,
- blurred vision,
- fatigue,
- nervousness,
- sweating,
- cough,
- anxiety,
- irritability,
- decreased urination,
- itching, and
- hunger,
- fast heartrate,
- difficulty swallowing,
- vision loss,
- shakiness,
- shock
- upper abdominal pain,
- a lump in the neck,
- spots or dark strings floating in your vision,
- fluctuating vision,
- dark or empty areas in your vision,
- clamminess,
- impatience,
- swelling in your legs, ankles, or feet,
The following drugs are related to Ozempic, either as a replacement or used together:
- Brenzavvy (bexagliflozin tablets)
- Diabinese (chlorpropamide)
- Qternmet XR (dapagliflozin, saxagliptin, and metformin hydrochloride)
- Trijardy XR (empagliflozin, linagliptin, and metformin hydrochloride extended-release tablets)
- Glucotrol (glipizide)
- Gvoke (glucagon injection)
- NovoLog (insulin aspart [rdna origin] inj)
- Toujeo U 300 (insulin glargine injection for subcutaneous use)
- Riomet ER (metformin hydrochloride for extended-release oral suspension)
- Starlix Tablet (nateglinide)
- Prandin (repaglinide)
- Prednisolone (prednisolone tablets)
- Rybelsus (semaglutide tablets)